December 2021

Flow cytometry is a powerful quantitative and preparative tool, allowing for the analytical interrogation of single cells amongst potentially millions of cells in minutes. Since its inception in 1953 and commercial popularisation in the 1970s, flow cytometry has emerged as a leading and sophisticated technology in applying the high-resolution characterisation of single cells within complex cellular networks. Challenges remain, however, and in our first biomarkers discussion group we bring together an exclusive panel of key opinion leaders to discuss the key factors behind the market’s growth, priorities, future outlook & challenges.


Discussion Points:

• Validating flow cytometry techniques 
• Developing high-throughput approaches & improving robustness 
• Data management strategies, including informatics, sample delivery & AI/ML approaches 
• Multiplexed high-throughput flow cytometry for drug discovery & repurposing 
• Regulatory perspectives on the various barriers/challenges of flow-based testing  

Discussion Group Leaders:

• Larry A. Sklar,
  Distinguished Professor Emeritus, University of New Mexico
• Maria Hernandez-Fuentes,
  Head of Huma Tissue Technologies, UCB